Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06627647 · ClinicalTrials.gov registry record · Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
A Phase 3 study of Non-squamous Non-small Cell Lung Cancer, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 878
- Enrollment target
- 20
- Study locations
NCT06627647: Recruiting Phase 3 study of Non-squamous Non-small Cell Lung Cancer, sponsored by AstraZeneca.
NCT06627647 is a Phase 3 study of Non-squamous Non-small Cell Lung Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 878 participants, above the 300-participant average among 9 other Non-squamous Non-small Cell Lung Cancer trials with a reported enrollment target (193% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06627647, a Phase 3 study of Non-squamous Non-small Cell Lung Cancer, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 878 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with non-squamous mNSCLC whose tumors express PD-L1.
Primary Outcome
OS is defined as the time from randomization until the date of death due to any cause.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG Rilvegostomig
Study Locations (20)
California
- Research Site - Anaheim
- Research Site - Beverly Hills
- Research Site - Loma Linda
- Research Site - Redlands
- Research Site - San Diego
- Research Site - San Francisco
- Research Site - Santa Rosa
- Research Site - Walnut Creek
Florida
- Research Site - Bay Pines
- Research Site - Fort Lauderdale
- Research Site - Gainesville
- Research Site - Jacksonville
- Research Site - Miami
Arizona
- Research Site - Chandler
- Research Site - Phoenix
Connecticut
- Research Site - Stamford
- Research Site - West Haven
Alabama
- Research Site - Mobile
Colorado
- Research Site - Lone Tree
Delaware
- Research Site - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 878 participants |
| Start Date | 2024-11-27 |
| Est. Completion | 2030-03-25 |
| Phase | Phase 3 |
What NCT06627647 shows while recruiting
NCT06627647 is an interventional study that assigns participants to a tested intervention. The registered 878 participants enrollment target is mid-sized for trials with a published cap, above the 300-participant average among 9 other Non-squamous Non-small Cell Lung Cancer trials with a reported enrollment target (193% higher).
The record links to 1 condition, with Non-squamous Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06627647 names 20 study sites across 7 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06627647 about?
NCT06627647 is a clinical study titled "A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC". The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with non-squamous mNSCLC whose tumors express PD-L1.
What is the current status of trial NCT06627647?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 878 participants. The study started on 2024-11-27. Estimated completion is 2030-03-25.
What conditions does trial NCT06627647 study?
This clinical trial studies the following conditions: Non-squamous Non-small Cell Lung Cancer.
What interventions are being tested in trial NCT06627647?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG), Rilvegostomig (DRUG).
Who is sponsoring clinical trial NCT06627647?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06627647 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-squamous Non-small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06627647's enrollment target sits among peer trials
878 1st of 9 higher than 9 of 9 other Non-squamous Non-small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-squamous Non-small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase III Study of AK112 for NSCLC Patients
ACTIVE NOT RECRUITING · Phase 3
-
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation
COMPLETED · Phase 3
-
A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
COMPLETED · Phase 3
-
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 2
-
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07076199 · 877 participants · Phase 3
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
- NCT05174286 · 880 participants · NA
Community Health Workers United to Reduce Colorectal Cancer and Cardiovascular Disease Among People at Higher Risk
- NCT05454280 · 880 participants · Phase 3
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
- NCT05525663 · 880 participants · NA
Physical Rehabilitation for Older Patients With Acute Heart Failure With Preserved Ejection Fraction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI